Announcements Trials
Browse Landscape

Status

Active not recruiting 1

Sponsor Class

OTHER 1

Study Type

Observational 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Pancreatic Neoplasms 45Neoplasms 5Colorectal Neoplasms 5Neoplasm Metastasis 3Adenocarcinoma 3Resectable Pancreatic Cancer 2Rectal Neoplasms 2Pancreatic Cancer Metastatic 2Carcinoma, Hepatocellular 2Biliary Tract Neoplasms 2Stomach Neoplasms 1Pancreatic Ductal Adenocarcinoma (PDAC) 1Pancreatic Cancer Non-resectable 1Pancreatic Adenocarcinoma 1Neoplasms, Basal Cell 1Locally Advanced Pancreatic Adenocarcinoma 1Localized Pancreatic Adenocarcinoma 1Gastrointestinal Neoplasms 1Gastroesophageal Adenocarcinoma 1Gastro-enteropancreatic neuroendocrine tumor 1Diabetes Mellitus, Insulin-Dependent, 12 1Colorectal Cancer Metastatic 1Colonic Neoplasms 1Cholangiocarcinoma 1Carcinoma, Pancreatic Ductal 1Carcinoma, Islet Cell 1Carcinoma 1Borderline Resectable Pancreatic Cancer 1

Interventions

Gemcitabine 2spartalizumab 1sargramostim 1folfirinox 1Taxes 1Surgical Procedures, Operative 1Specimen Handling 1Radiotherapy 1Pancreaticoduodenectomy 1Magnetic Resonance Spectroscopy 1Leucovorin 1Laparoscopy 1Fluorouracil 1Drug Therapy 1Colony-Stimulating Factors 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Locally Advanced Pancreatic Adenocarcinoma × folfirinox × Gastrointestinal × Clear all
NCT04423731 2024-11-20

Neoadjuvant Chemotherapy in Borderline Resectable and Locally Advanced Pancreatic Cancer (NORPACT-2)

Oslo University Hospital

Active not recruiting
251 enrolled
Gastrointestinal

Locally Advanced Pancreatic Adenocarcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡